This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

FDA Advisory Panels: A Coin Flip

BOSTON ( TheStreet) -- Investors who think they can predict the outcome of U.S. Food and Drug Administration advisory panels this year might be better off just flipping a coin.

FDA advisory committees have become much tougher in 2010 with only a bit more than half of drugs taken in front of panels receiving positive recommendations, according to an analysis conducted by Concept Capital, the healthcare policy research arm of Sanders Morris Harris.

As of August 26, FDA advisory committees have recommended approval 12 out of 23 times, or a rate of just 52%, according to Concept Capital.

"The percentage of 'yes' recommendations is down significantly compared to 2009 and 2008, when 75% and 80% of drugs received positive recommendations," said Ramsey Baghdadi, an analyst with Concept Capital.

Notable "no" votes from advisory panels this year include Cell Therapeutics' (CTIC) lymphoma drug pixantrone, Vivus' (VVUS) obesity drug Qnexa, Acura Pharmaceuticals' (ACUR) pain drug Acurox and Jazz Pharmaceuticals' (JAZZ) fibromylagia drug JZP-6.

The 52% rate of positive votes is similar to the 50% rate in 2007, considered to be one of the worst regulatory periods for the pharmaceutical and biotech sectors in years, said Concept Capital, in its analysis.

So far this year, the Oncologic Drugs Advisory Committee has voted against approval for all three cancer drugs it has reviewed this year. Conversely, the Peripheral and Central Nervous System Drugs Advisory Committee has been the most amenable, recommending approval all three times for drugs from Questcor Pharmaceuticals (QCOR), Novartis (NVS) and Valeant Pharmaceuticals (VRX).

Concept Capital's Baghdadi says FDA advisory panels have become more unpredictable for two main reasons: First, the FDA is bringing more drugs in front of advisory panels due to changes in FDA law that require most new drugs to be reviewed by outside experts. Second, stricter conflict of interest rules implemented by FDA have made it more difficult for the agency to recruit experienced panel members.

Despite the tougher stance at FDA advisory panels, Concept Capital believes the overall environment for drug approvals at FDA is improved compared to prior years.

Concept Capital limited its analysis to new molecular entities and major new indications for currently approved drugs that were reviewed by advisory panels attached to the FDA's Center for Drug Evaluation and Research.

A broader look at FDA advisory panel, including biologic drugs and those reviewed by other FDA divisions offers a bit more optimistic picture -- 15 "yes" votes from 27 panels, or a 56% rate.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs